STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Artivion (NYSE: AORT) SVP Jean Holloway reports Form 4 stock sales

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Artivion, Inc. executive Jean F. Holloway, the company’s SVP and General Counsel, reported open-market sales of company stock. On 12/03/2025, she sold 2,048 shares of Artivion common stock at a price of $45.3 per share and, in a separate transaction the same day, sold an additional 5,267 shares at $45.3 per share.

Following these transactions, Holloway beneficially owns 156,093 shares of Artivion common stock directly. The filing is a standard Form 4 disclosure of insider trading activity required for company officers.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Holloway Jean F

(Last) (First) (Middle)
1655 ROBERTS BLVD., NW

(Street)
KENNESAW GA 30144

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, General Counsel
3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/03/2025 S 2,048 D $45.3(1) 161,360 D
Common Stock 12/03/2025 S 5,267 D $45.3(1) 156,093 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects the price the shares were sold.
Remarks:
/s/ Jean F Holloway 12/04/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artivion (AORT) report in this Form 4?

The filing reports that Jean F. Holloway, Artivion’s SVP and General Counsel, sold shares of Artivion common stock in open-market transactions on 12/03/2025.

How many Artivion (AORT) shares did Jean F. Holloway sell and at what price?

Jean F. Holloway sold 2,048 shares of Artivion common stock at $45.3 per share and 5,267 shares at $45.3 per share on 12/03/2025.

How many Artivion (AORT) shares does Jean F. Holloway own after the reported sales?

After the reported transactions, Jean F. Holloway beneficially owns 156,093 shares of Artivion common stock directly.

What is Jean F. Holloway’s role at Artivion (AORT)?

Jean F. Holloway is an officer of Artivion, serving as SVP, General Counsel, according to the Form 4.

Does this Artivion (AORT) Form 4 involve any derivative securities?

No derivative securities are listed as acquired, disposed of, or beneficially owned in Table II of the Form 4; only common stock transactions are reported.

Is the reported Artivion (AORT) insider transaction a joint filing?

No. The Form 4 indicates it is filed by one reporting person, Jean F. Holloway.
Artivion, Inc.

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Latest SEC Filings

AORT Stock Data

2.15B
43.28M
4.5%
89.88%
2.32%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
KENNESAW